Article

Company halts study of IC drug due to positive results

Urigen Pharmaceuticals has announced the early closure of its study of a drug known as URG101 due to positive, statistically significant interim analysis results in both the primary and all secondary endpoints. Top-line results of the interim analysis, which was planned at 50% enrollment, were previously released March 12.

Urigen Pharmaceuticals has announced the early closure of its study of a drug known as URG101 due to positive, statistically significant interim analysis results in both the primary and all secondary endpoints. Top-line results of the interim analysis, which was planned at 50% enrollment, were previously released March 12.

The URG101-104 study was a pharmacodynamic and safety study investigating the treatment of painful bladder syndrome/interstitial cystitis. According to the manufacturer, the study design provided sufficient power to reliably assess treatment effects across modestly sized cohorts; thus, continuing enrollment would not meaningfully alter the study conclusions of safety and tolerability. Accelerated development of the drug is anticipated.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Anna Myers, CNP, answers a question during a Zoom video interview
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.